Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 07, 2018

SELL
$15.5 - $21.41 $1.55 Million - $2.14 Million
-100,000 Closed
0 $0
Q2 2018

Aug 15, 2018

BUY
$17.15 - $17.79 $1.71 Million - $1.78 Million
100,000 New
100,000 $1.73 Million

Others Institutions Holding KZR

About Kezar Life Sciences, Inc.


  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $512M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.